| Literature DB >> 35878167 |
Leticia Diez-Quijada1, María Puerto1, Daniel Gutiérrez-Praena1, Maria V Turkina2, Alexandre Campos3, Vitor Vasconcelos3,4, Ana M Cameán1, Ángeles Jos1.
Abstract
Cyanotoxins are secondary metabolites produced by different types of cyanobacteria. Among them, Cylindrospermopsin (CYN) and Microcystins (MCs) stand out due to their wide geographical distribution and toxicity in various organs, including the kidney, which is involved in their distribution and elimination. However, the renal toxicity caused by CYN and MCs has hardly been studied. The aim of this work was to assess the cytotoxicity effects caused by CYN and MC-LR in the renal cell line HEK293, and for the first time, the influence of CYN on the gene expression of selected genes in these cells by quantitative real-time PCR (qRT-PCR). CYN caused an upregulation in the gene expression after exposure to the highest concentration (5 µg/mL) and the longest time of exposure (24 h). Moreover, shotgun proteomic analysis was used to assess the molecular responses of HEK293 cells after exposure to the individuals and combinations of CYN + MC-LR. The simultaneous exposure to both cyanotoxins caused a greater number of alterations in protein expression compared to single toxins, causing changes in the cellular, lipid and protein metabolism and in protein synthesis and transport. Further studies are needed to complete the toxicity molecular mechanisms of both CYN and MC-LR at the renal level.Entities:
Keywords: Cylindrospermopsin; HEK293 cells; Microcystin-LR; qRT-PCR; shotgun proteomics
Mesh:
Substances:
Year: 2022 PMID: 35878167 PMCID: PMC9316492 DOI: 10.3390/toxins14070429
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 5.075
Figure 1The effect of CYN on the viability of HEK293 cells. Viability was determined with the MTS assay (a) and TP (b) after exposure to 0–25 µg/mL CYN for 4, 24 and 48 h. Significantly different from the control group * p < 0.05 and ** p < 0.01.
Figure 2The effect of MC-LR on the viability of HEK293 cells. Viability was determined with the MTS assay (a) and TP (b) after exposure to 0–200 µg/mL MC-LR for 4, 24 and 48 h. Significantly different from control group * p < 0.05 and ** p < 0.01.
Effects of CYN on the expression of mRNA of selected genes involved in xenobiotic metabolism, DNA damage responsive, oxidative stress response and apoptosis/survival in HEK293 cells. The cells were exposed to CYN (0.5 and 5 µg/mL) for 4 and 24 h. B(a)P 30 µM was used as positive control.
| Mechanisms Involved | Gene Symbol | CYN (µg/mL) | 4 h | 24 h | Entrez Gene Name |
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | ||||
| Xenobiotic Metabolism |
| C- | 1.13 ± 0.67 | 1.03 ± 0.33 | Cytochrome P450 family 1 Subfamily A member 1 |
| 0.5 | 1.11 ± 0.11 | 1.06 ± 0.35 | |||
| 5 |
|
| |||
| B(a)P 30 µM | 1.03 ± 0.05 | 2.16 ± 0.33 | |||
|
| C- | 1.01 ± 0.19 | 1.02 ± 0.25 | Cytochrome P450 family 1 Subfamily A member 2 | |
| 0.5 | 0.90 ± 0.50 |
| |||
| 5 | 0.87 ± 0.06 |
| |||
| B(a)P 30 µM | 1.23 ± 0.40 | 1.23 ± 0.18 | |||
| DNA damage responsive |
| C- | 1.05 ± 0.19 | 1.00 ± 0.12 | Tumor protein P53 |
| 0.5 | 0.86 ± 0.21 | 1.14 ± 0.25 | |||
| 5 | 0.98 ± 0.23 |
| |||
| B(a)P 30 µM | 0.9 ± 0.20 | 1.22 ± 0.21 | |||
|
| C- | 1.03± 0.30 | 1.01 ± 0.17 | Cyclin Dependent Kinase Inhibitor 1A | |
| 0.5 | 0.72 ± 0.14 |
| |||
| 5 | 1.01 ± 0.56 |
| |||
| B(a)P 30 µM | 0.88 ± 0.29 | 1.06 ± 0.68 | |||
| Oxidative stress |
| C- | 1.08 ± 0.47 | 1.01 ± 0.20 | Superoxide dismutase 1 |
| 0.5 | 1.08 ± 0.28 | 1.30 ± 0.25 | |||
| 5 |
| 1.10 ± 0.68 | |||
| B(a)P 30 µM | 1.04 ± 0.13 | 1.05 ± 0.21 | |||
|
| C- | 1.08 ± 0.48 | 1.00 ± 0.13 | Catalase | |
| 0.5 | 1.41 ± 0.52 |
| |||
| 5 |
|
| |||
| B(a)P 30 µM | 1.21 ± 0.11 | 1.17 ± 0.10 | |||
|
| C- | 1.05 ± 0.43 | 1.05 ± 0.39 | Glutathione peroxidase 1 | |
| 0.5 | 1.04 ± 0.22 |
| |||
| 5 | 0.89 ± 0.27 |
| |||
| B(a)P 30 µM | 1.22 ± 0.18 | 1.36 ± 0.58 | |||
| Apoptosis/survival |
| C- | 1.02 ± 0.22 | 1.01 ± 0.14 | Apoptosis regulator |
| 0.5 | 0.74 ± 0.17 | 1.30 ± 0.25 | |||
| 5 | 0.99 ± 0.30 | 0.92 ± 0.22 | |||
| B(a)P 30 µM | 0.87 ± 0.10 | 1.14 ± 0.24 | |||
|
| C- | 1.01 ± 0.15 | 1.01 ± 0.16 | B-cell CLL/lymphoma 2 | |
| 0.5 | 0.78 ± 0.21 | 1.33 ± 0.26 * | |||
| 5 | 1.07 ± 0.02 |
| |||
| B(a)P 30 µM | 0.79 ± 0.01 |
|
The results are expressed as relative mRNA expression normalized to the control group. Data are mean ± SD of three independent experiments. Significant differences between CYN-treated cells and the control group are indicated by * p < 0.05, ** p < 0.01 and *** p < 0.001 (One-way analysis of variance (ANOVA) with Dunnett’s Multiple Comparison Test and the non-parametric Kruskal–Wallis test followed by Dunn’s multiple comparison test). Bold values show the up- or down-regulation of genes.
Figure 3Analysis of HEK293 cells after exposure to cyanotoxins. The color map symbolizes the relative expression of proteins displaying quantitative variations among experimental groups (ANOVA, p < 0.01). Proteins are presented in lines and group samples in columns. Control group (C), MeOH (solvent control group), group exposed to Cylindrospermopsin (CYN), group exposed to Microcystin-LR (MC) and group exposed to the combination of Cylindrospermopsin and Microcystin-LR (CYN + MC). Numbers preceding group abbreviations indicate toxin concentrations.
Differential protein expression in HEK293 cells exposed to CYN (0.5 and 1 µg/mL), MC-LR (1 µg/mL) or their combination of both toxins compared to the control. Quantitative expression is reported as normalized arbitrary units (AU). Significant differences between treated cells and the control group are indicated by * p < 0.05 and ** p < 0.01 (ANOVA).
| AU | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Functional Category | Protein Name | Gene | C | 0.5 CYN | 1 CYN | 1 MC-LR | 0.5CYN + 1MCLR | 1CYN + 1MC-LR | ||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |||
| Cellular metabolism | Carbonyl reductase [NADPH] 1 |
| 2.3 × 10−4 | 2.6 × 10−4 | 4.7 × 10−4 | 3.7 × 10−4 | 9.0 × 10−4 | 5.3 × 10−4 | 9.0 × 10−4 | 3.0 × 10−4 | 8.7 × 10−4 | 1.7 × 10−4 | 1.6 × 10−3 ** | 4.5 × 10−4 |
| Phosphoglucomutase-2 |
| 1.0 × 10−8 | 0 | 1.0 × 10−8 | 9.0 × 10−5 | 1.0 × 10−8 | 0 | 1.0 × 10−8 | 0 | 2.8 × 10−4 ** | 1.7 × 10−4 | 1.0 × 10−8 | 0 | |
| Lipid metabolism | Prosaposin |
| 5.3 × 10−4 | 1.4 × 10−4 | 4.3 × 10−4 | 2.6 × 10−4 | 1.0 × 10−8 ** | 1.0 × 10−4 | 2.4 × 10−4 | 8.7 × 10−5 | 3.1 × 10−4 | 1.4 × 10−4 | 2.4 × 10−4 * | 1.4 × 10−4 |
| 3-ketoacyl-CoA thiolase, mitochondrial |
| 6.4 × 10−4 | 2.7 × 10−4 | 5.7 × 10−4 | 3.9 × 10−4 | 1.0 × 10−8 * | 1.3 × 10−4 | 4.3 × 10−4 | 2.7 × 10−4 | 1.4 × 10−4 | 2.7 × 10−4 | 1.0 × 10−8 * | 0 | |
| Protein | Moesin |
| 9.9 × 10−4 | 2.9 × 10−4 | 7.8 × 10−4 | 2.8 × 10−4 | 4.3 × 10−4 * | 2.6 × 10−4 | 5.9 × 10−4 | 8.0 × 10−5 | 4.1 × 10−4 * | 1.5 × 10−4 | 1.5 × 10−4 ** | 2.1 × 10−4 |
| Cell adhesion | Integrin beta-1 |
| 2.5 × 10−4 | 8.1 × 10−5 | 1.0 × 10−8 * | 7.9 × 10−5 | 1.0 × 10−8 * | 6.6 × 10−5 | 1.0 × 10−8 * | 7.4 × 10−5 | 1.0 × 10−8 ** | 0 | 1.0 × 10−8 ** | 0 |
| Fermitin family homolog 2 |
| 2.9 × 10−4 | 1.0 × 10−4 | 3.3 × 10−4 | 1.7 × 10−4 | 1.0 × 10−8 | 7.7 × 10−5 | 8.6 × 10−5 | 1.0 × 10−4 | 1.7 × 10−4 | 1.3 × 10−4 | 1.0 × 10−8 * | 0 | |
| Protein Metabolism | Bleomycin hydrolase |
| 1.0 × 10−8 | 0 | 1.0 × 10−8 | 0 | 1.0 × 10−8 | 0 | 1.0 × 10−8 | 2.4 × 10−4 | 4.8 × 10−4 * | 2.4 × 10−4 | 1.0 × 10−8 | 0 |
| Protein regulation | E3 SUMO-protein ligase RanBP2 |
| 4.1 × 10−5 | 3.2 × 10−5 | 3.7 × 10−5 | 2.1 × 10−5 | 1.2 × 10−4 * | 6.8 × 10−5 | 8.8 × 10−5 | 3.7 × 10−5 | 6.9 × 10−5 | 4.5 × 10−5 | 1.4 × 10−4 | 3.8 × 10−4 |
| E3 ubiquitin-protein ligase CHIP |
| 1.0 × 10−8 | 0 | 1.0 × 10−8 | 0 | 1.7 × 10−4 | 2.5 × 10−4 | 1.0 × 10−8 | 1.8 × 10−4 | 4.0 × 10−4 ** | 1.7 × 10−4 | 4.1 × 10−4 | 2.4 × 10−4 | |
| Protein SGT1 homolog |
| 4.3 × 10−4 | 1.8 × 10−4 | 3.9 × 10−4 | 3.1 × 10−4 | 1.0 × 10−8 * | 0 | 1.0 × 10−8 | 1.8 × 10−4 | 3.6 × 10−4 | 2.7 × 10−4 | 1.0 × 10−8 * | 0 | |
| ATP-dependent Clp protease proteolytic subunit, mitochondrial |
| 1.0 × 10−8 | 0 | 1.0 × 10−8 | 0 | 1.0 × 10−8 | 0 | 4.3 × 10−4 ** | 3.6 × 10−4 | 1.0 × 10−8 | 0 | 1.0 × 10−8 | 0 | |
| Protein synthesis | Translation initiation factor eIF-2B subunit alpha |
| 1.0 × 10−8 | 0 | 1.0 × 10−8 | 0 | 1.0 × 10−8 | 0 | 1.0 × 10−8 | 0 | 3.6 × 10−4 * | 1.8 × 10−4 | 1.0 × 10−8 | 2.0 × 10−4 |
| Treacle protein |
| 4.0 × 10−5 | 8.0 × 10−5 | 1.0 × 10−4 | 1.0 × 10−4 | 1.0 × 10−4 | 5.0 × 10−5 | 2.0 × 10−4 | 1.0 × 10−4 | 3.0 × 10−4 | 6.2 × 10−5 | 3.0 × 10−4 * | 9.3 × 10−5 | |
| 40S ribosomal protein S5 |
| 7.0 × 10−4 | 3.0 × 10−4 | 7.0 × 10−4 | 3.0 × 10−4 | 1.0 × 10−8 | 3.0 × 10−4 | 1.0 × 10−8 | 3.0 × 10−4 | 5.0 × 10−4 | 3.0 × 10−4 | 1.0 × 10−8 * | 0 | |
| Cisplatin resistance-associated overexpressed protein, isoform CRA_b |
| 1.0 × 10−8 | 1.3 × 10−4 | 1.5 × 10−4 | 2.5 × 10−4 | 4.1 × 10−4 ** | 1.2 × 10−4 | 2.5 × 10−4 | 2.0 × 10−5 | 2.5 × 10−4 | 1.0 × 10−4 | 3.0 × 10−4 | 5.2 × 10−5 | |
| Protein transport | Coatomer subunit gamma-1 |
| 7.0 × 10−4 | 5.1 × 10−5 | 3.2 × 10−4 * | 1.9 × 10−4 | 1.8 × 10−4 * | 2.5 × 10−4 | 2.2 × 10−4 * | 1.8 × 10−4 | 6.3 × 10−4 | 1.6 × 10−4 | 1.7 × 10−4 ** | 1.8 × 10−4 |